Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Lancet Oncol. 2017 Dec 5;19(1):51–64. doi: 10.1016/S1470-2045(17)30900-2

Figure 4: Progression-free survival (A) and overall survival (B) in patients with at least 6 months of follow-up (n=161) and according to PD-L1 expression status.

Figure 4:

PD-L1 expression based on a 5% expression staining threshold (n=139 evaluable). PD-L1=programmed death ligand 1.